Novanta Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 29, 2024; comparable period ended March 31, 2023. Figures are in U.S. dollars.
Business context
Novanta supplies technology components and subsystems to medical and advanced industrial OEMs. It reports three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. Medical products represented approximately 55% of revenue; advanced industrial products, 45%.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $230.9 million | $219.1 million |
| Gross profit / margin | $100.4 million / 43.5% | $97.6 million / 44.6% |
| Operating income | $25.6 million | $26.3 million |
| Net income | $14.7 million | $18.3 million |
| Diluted EPS | $0.41 | $0.51 |
| Operating cash flow | $32.8 million | $10.2 million |
| Capital expenditures | $6.4 million | $3.6 million |
Revenue rose 5.4%, but operating income declined 2.7% and net income declined 19.7%. Higher SG&A and amortization partly offset increased gross profit. Net interest expense increased to $8.3 million from $6.3 million; the weighted-average senior-facility interest rate was 6.54%, versus 5.55%.
At March 29, 2024, cash was $93.5 million, total debt under senior credit facilities was $513.7 million, and net debt was approximately $420.2 million. Unused and available revolving-credit capacity was $254.4 million. The current ratio was approximately 2.8. The company reported covenant compliance: leverage ratio 2.31 against a 3.50 maximum, and fixed-charge coverage 4.22 against a 1.50 minimum. Management expects operating cash flows to cover operating and capital spending needs for at least the next 12 months.
Material changes versus the prior period
- Motion Solutions was acquired on January 2, 2024, for approximately $192 million in cash, financed with revolver borrowings. It contributed $21.2 million of revenue and a $2.0 million pretax loss; the loss included $2.8 million of inventory fair-value adjustment amortization and $2.7 million of acquired-intangible amortization.
- Medical Solutions revenue increased 32.0% to $102.5 million, largely reflecting the acquisition and higher detection and analysis sales. Precision Medicine and Manufacturing revenue fell 6.2% to $65.2 million, and Robotics and Automation revenue fell 12.1% to $63.2 million, principally due to weaker advanced-industrial demand and customer inventory timing.
- Total gross margin decreased 1.1 percentage points. Medical Solutions margin fell to 38.4% from 41.1%, including acquisition-related amortization and inventory adjustments; Precision Medicine and Manufacturing margin declined to 48.7% from 49.4%. Robotics and Automation margin improved to 48.3% from 45.6% on better factory efficiency.
- Operating cash flow improved year over year, which management attributed primarily to better working-capital management. Investing cash outflow increased to $197.6 million, primarily due to the acquisition.
Outlook, commentary, and risks
- No company-wide revenue or EPS guidance is stated in the provided filing text. Novanta expects 2024 capital expenditures of approximately $20 million to $25 million, including a U.K. facility buildout.
- The 2024 restructuring program is expected to be substantially completed by year-end. The company expects an additional $4.5 million to $5.5 million of charges beyond the $0.5 million recorded in Q1.
- Management described continued inflation in materials, components, and labor; pricing and productivity actions have generally helped offset costs, but full recovery is not assured. Higher interest rates have increased financing costs and contributed to some OEM customers deferring capital-equipment orders.
- Key risks include demand fluctuations and customer order timing, acquisition integration, supply-chain constraints, foreign-exchange and interest-rate movements, medical-device regulation, cybersecurity, and the company’s indebtedness. Management does not expect ordinary-course legal claims to have a material adverse effect, but provides no assurance of outcomes.
- The Motion Solutions purchase-price allocation is preliminary and may change during the measurement period. Disclosure controls were judged effective at quarter-end; the filing reports no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether Motion Solutions integration, acquired margins, and expected synergies support returns on the acquisition and associated debt.
- Whether advanced-industrial demand and customer inventory conditions recover, and whether gross margins stabilize.
- Debt, interest expense, borrowing capacity, and covenant headroom as rates and operating performance change.
- Final acquisition purchase-price allocation and the timing and total costs of restructuring and planned capital spending.